)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Biohit
Biohit (BIOBV) investor relations material
Biohit H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary5 Aug, 2026
Executive summary
Revenue for January–June 2026 rose 5.7% year-over-year to EUR 7.8 million, with operating profit up 28.6% to EUR 1.5 million and an improved margin of 19.4%.
GastroPanel product line saw sales increase by 90.1% year-over-year, driving profitability and international growth.
International operations contributed 98.7% of total revenue, with notable expansion in Latin America and the UK.
The Italian subsidiary was discontinued in favor of a distributor model, improving profitability despite lower sales.
Financial highlights
Operative EBITDA reached EUR 1.7 million (21.9% of revenue), up from EUR 1.4 million (18.3%) year-over-year.
Earnings per share increased to EUR 0.09 (undiluted), up 39.6% from the prior year.
Profit for the period was EUR 1.3 million, up 39.7% year-over-year.
Equity ratio improved to 78.9% from 74.1% a year earlier.
Cash and cash equivalents at period end were EUR 1.6 million, down from EUR 3.9 million in the prior year.
Outlook and guidance
2026 revenue is expected to reach EUR 16.5–17.3 million, representing 5–10% growth over 2025, with an operating margin of at least 10%.
Strategic targets for 2024–2028 include annual revenue growth of 15–20% and EBIT of at least 10% of revenue.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biohit
- 2025 revenue up 10.1%, strong royalty growth, cautious 2026 outlook amid slower GastroPanel uptake.BIOBV
H2 2025 - Flat revenue, robust international growth, and strong margins support a positive 2025 outlook.BIOBVH1 2025
- Revenue up 14% to EUR 7.4m, with strong international sales and robust equity ratio.BIOBVH1 2024
- Biohit achieved robust growth and margin expansion in 2024, with a positive outlook for 2025.BIOBVH2 2024
Next Biohit earnings date
H2 202611 Feb, 2027
Biohit
Next Biohit earnings date
H2 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Biohit Oyj is a Finland-based biotechnology company specializing in the development and production of diagnostic tests and laboratory instruments. The company’s product portfolio includes enzyme immunoassay tests, liquid handling devices, and solutions for the detection and monitoring of gastrointestinal diseases and conditions. The company is headquartered in Helsinki, Finland, and its shares are listed on the Nasdaq Helsinki.